Home › Chemotherapy › Which Chemotherapy Drugs — Cause Nerve Damage?

Nerve side effects

Which Chemotherapy Drugs Cause Nerve Damage?

Medically reviewed by Dr. Naresh Gundu, Medical Oncologist, MBBS (Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar) · DNB Internal Medicine (Sir Gangaram Hospital, New Delhi) · DM Medical Oncology (AIIMS) · Last reviewed September 2026

Tingling, numbness, and weakness in the hands and feet are common side effects of some chemotherapy drugs. Three groups cause most of the damage: platinums, taxanes, and vinca alkaloids. Whether it goes away depends largely on which drug caused it.

Prescription-only medicine.

These are prescription-only medicines given under specialist supervision in a hospital or clinic. Nothing on this page should be used to start, adjust, or stop any chemotherapy treatment. It is not suitable for everyone — see who this is not for below.

Talk to an oncologist

Leave your details and a member of the oncology team will call you back to answer questions about your treatment plan.

No charge for the call, and no obligation to book anything.

412Chemotherapy pages, written and reviewed

17Oncologists on the panel

10Centres across Hyderabad

41Locations across two states

In short

The main chemotherapy drugs that cause nerve damage are the platinum agents, the taxanes, and the vinca alkaloids. How likely you are to develop it depends on which drug, how much has been given, and your own nerve health. Whether it reverses is different for each group — and that difference matters when your team is planning your treatment.

In detail

Which chemotherapy drugs damage nerves?

Three groups of chemotherapy drugs cause most nerve damage, according to ASCO and NCCN guidance on chemotherapy-induced peripheral neuropathy. These are the platinum drugs, the taxanes, and the vinca alkaloids.

The platinum drugs most commonly responsible are oxaliplatin (sold in India as Oxali and other generics) and cisplatin (known as Kemoplat and Platikem, among others). Oxaliplatin is used mainly in colorectal cancer. Cisplatin is used across lung, head and neck, bladder, and gynaecological cancers. Carboplatin, a third platinum, carries lower neuropathy risk but is not risk-free.

Among taxanes, paclitaxel (Intaxel, Taxol) and nab-paclitaxel (Abraxane) carry the highest risk. Docetaxel (Docel, Taxotere) causes less. Among vinca alkaloids, vincristine is most likely to cause nerve damage — and unlike the others, it can also cause motor weakness, not just numbness and tingling.

In detail

Does the nerve damage go away?

Reversibility varies meaningfully by drug group. This is one of the most important questions to raise before treatment starts, because the answer is different for each drug.

Taxane neuropathy often improves after treatment ends. Many patients recover over several months, though some are left with lasting symptoms, particularly after higher cumulative doses.

Platinum neuropathy divides into two patterns. Oxaliplatin causes both an acute cold-triggered reaction — nearly always temporary — and a cumulative neuropathy that builds over cycles and can persist for months to years. Cisplatin neuropathy is more often long-lasting and can worsen for a period even after treatment stops, a pattern ESMO guidelines call coasting.

Vincristine neuropathy tends to recover slowly. Motor weakness — difficulty gripping or lifting a foot — is less reliably reversible than tingling and numbness.

Eligibility

Who these medicines are not for

The drugs discussed on this page are not used in every patient with cancer. Eligibility is always decided by an oncologist based on the individual case.

Pre-existing significant neuropathy: Patients with existing nerve damageFrom diabetes, prior chemotherapy, alcohol use, or inherited conditions — are generally not given these agents, as they can worsen existing damage.
Severely reduced kidney function: Cisplatin in particular is not given when kidney function is significantly impaired, as the drug accumulates to toxic levels when clearance is poor.
Significantly reduced liver function: Taxanes and vinca alkaloids are processed by the liver; serious liver disease affects how safely they can be given.
Pregnancy: Chemotherapy carries serious risk to a developing pregnancy. Use at any stage requires individual specialist assessment of risk and benefit.
Very poor general fitness: Patients who are not well enough to tolerate the expected side effects are generally not candidates for these agents.

Want to talk this through with an oncologist?

Leave your number and an oncology coordinator will call you back at a time that suits you.

Worth knowing

Did you know?

Chemotherapy-induced peripheral neuropathy is one of the most common reasons a dose is reduced or treatment is paused. ASCO identifies it as a leading cause of treatment modification across multiple cancer types.

Reporting symptoms early keeps the milder response options available.

Source: ASCO Clinical Practice Guideline: Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy

Question by question

What does each drug do differently to the nerves?

Oxaliplatin: two types of neuropathy with different outlooks

Oxaliplatin causes two distinct problems. The first is an acute reaction during or just after infusion, often triggered by cold — touching cold water or breathing cold air. This settles between cycles for most patients and is nearly always temporary. The second is a cumulative neuropathy that builds with each cycle as damage accumulates in the sensory nerves. This type can persist for months to years after treatment ends, and in some patients does not fully resolve. Your oncologist will ask about both types at each review, and a significant worsening of cumulative symptoms is usually a reason to discuss adjusting the treatment.

Cisplatin: damage that can worsen even after treatment stops

Cisplatin concentrates in the sensory nerve cell bodies over time. Because of this accumulation, neuropathy from cisplatin can continue to worsen for weeks to months after the last dose — a pattern ESMO and ASCO guidance call coasting. Recovery is possible but is often partial rather than complete. Patients with diabetes or existing nerve damage are more likely to be left with long-term symptoms. Your team weighs this risk against the benefit cisplatin provides for your specific cancer when selecting and adjusting your treatment plan.

Paclitaxel and other taxanes: tingling in the hands and feet

Paclitaxel, nab-paclitaxel and to a lesser degree docetaxel cause mainly sensory neuropathy — tingling, numbness, and sometimes burning pain, typically in the feet and hands in a symmetrical pattern. Symptoms tend to be related to the total dose given over time. Neuropathy often improves after treatment ends, and for many patients it resolves substantially over several months. Weekly schedules at lower individual doses can produce more cumulative neuropathy than three-weekly higher doses, and your oncologist accounts for this when choosing your regimen.

Vincristine: the drug that can also cause weakness

Vincristine affects both sensory and motor nerves. The sensory symptoms — tingling and numbness in the feet and hands — are similar to those from other drugs. What makes vincristine different is that it can also cause motor weakness: difficulty gripping, trouble with buttons, or foot drop. Weakness is a more serious symptom than numbness and should be reported to your team promptly rather than at the next scheduled appointment. Recovery from vincristine neuropathy tends to be slow, and motor weakness is less reliably reversible than sensory symptoms.

Which patients are more likely to develop significant neuropathy?

Pre-existing nerve damage is the strongest individual risk factor. Patients with diabetes, heavy alcohol use, inherited neuropathies, or previous chemotherapy that affected the nerves are more likely to develop significant neuropathy — often at lower cumulative doses than would affect someone with healthy nerves. Older age and certain nutritional deficiencies also increase risk. Your oncologist uses this information when deciding which drug to use, at what dose, and whether to adjust the plan if symptoms begin to emerge during treatment.

What happens when neuropathy interferes with daily life?

When neuropathy significantly affects daily activities — writing, walking steadily, fastening clothes — ASCO and NCCN guidance supports a dose reduction, a schedule change, or stopping the drug responsible. These modifications are standard responses to moderate or severe neuropathy and are not a sign of treatment failure. Duloxetine is the one agent ASCO recommends for symptom relief in established neuropathic pain from chemotherapy, though it manages symptoms rather than reversing nerve damage. Any decision to modify the chemotherapy dose is made by balancing toxicity against treatment effectiveness for your specific situation.

Still have a question about your treatment? Tell us what is on your chart and an oncologist will explain what it means for you, what to expect and what your schedule is likely to look like.

Talk to an oncologist 1800 202 8726

Common questions

Frequently asked questions

How do I know if the tingling in my fingers is from chemotherapy?

The timing is the most useful clue. Neuropathy from chemotherapy typically begins during or after treatment, often building gradually over cycles rather than appearing all at once. It usually appears first in the feet and hands in a symmetrical pattern rather than on one side of the body or in a single limb. If tingling appeared before treatment started, or appears only on one side, your team will want to look for other causes. Tell your oncologist or nurse about any new tingling at your next visit — it is one of the symptoms they are actively monitoring.

Can neuropathy be prevented while on chemotherapy?

No prevention strategy has been shown to reliably reduce chemotherapy-induced peripheral neuropathy, and ASCO's clinical practice guideline states that no agent can be recommended for this purpose based on current evidence. Some research continues into approaches such as cryotherapy during infusion, but results are mixed and practice varies between centres. The most effective available approach is monitoring symptoms closely at each cycle so that dose adjustments can be made before damage becomes severe. Tell your team about tingling or numbness early — do not wait until it significantly affects your daily life.

Will the nerve damage go away completely after chemotherapy ends?

It depends on which drug caused it and how severe it became. Taxane neuropathy often improves substantially over months, and full or near-full recovery is common when symptoms were mild or moderate. Oxaliplatin's cumulative neuropathy is more variable — many patients improve over one to two years, but a proportion are left with persistent symptoms. Cisplatin neuropathy is the most likely to be long-lasting, and complete recovery is less common. Your oncologist can give a more specific picture based on which drug you are on and what your current symptoms are.

Is weakness more serious than tingling and numbness?

Yes. Tingling and numbness indicate that sensory nerves are affected — uncomfortable, but in its mild form this does not usually affect safety in daily life. Weakness — difficulty gripping, dropping things, or trouble lifting your foot when walking — means motor nerves are also involved. Vincristine is the drug most associated with motor neuropathy. Weakness should be reported to your team promptly rather than at a scheduled visit, because it can progress and is less likely to fully reverse than sensory symptoms.

Does a dose reduction for neuropathy mean the treatment will be less effective?

Not necessarily. ASCO and NCCN guidance supports dose modification as a standard response to significant neuropathy precisely because the aim is to continue treating the cancer safely rather than to stop. Your oncologist will weigh how severe the neuropathy is against how well the treatment appears to be working and how close you are to completing it. Many patients complete treatment at a modified dose and achieve the intended result. If you are concerned whether a modified dose is still working, ask your oncologist directly — it is a specific and answerable question.

Are there medicines that help once neuropathy has developed?

Duloxetine is the one medicine ASCO's clinical practice guideline recommends for pain from established chemotherapy-induced neuropathy. It does not reverse nerve damage but can reduce pain and improve daily function in some patients. Other medicines used in practice for neuropathic pain — including gabapentin and pregabalin — have less specific evidence for chemotherapy-related neuropathy. Ask your oncologist or palliative care team whether any of these is appropriate for your symptoms rather than starting them without guidance, as some interact with other treatments.

Who would be treating you

The medical oncologists on the CION panel

Chemotherapy is prescribed, dosed and supervised by a medical oncologist. These are the six on the CION panel.

Dr. Naresh Gundu

Medical Oncologist

MBBS · DNB Internal Medicine (Sir Gangaram, New Delhi) · DM Medical Oncology (AIIMS)

Call Book appointment

Dr. C. Raghavendra Reddy

Medical Oncologist

MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Kukatpally

Call Book appointment

Dr. Bharati Devi Gorantla

Medical Oncologist

MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK)

Call Book appointment

Dr. Owais Mohammed

Medical Oncologist

Call Book appointment

Dr. T. Raghavender Reddy

Medical Oncologist

MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · L.B. Nagar

Call Book appointment

Dr. N. Kiranmayee

Medical Oncologist

Call Book appointment

Which oncologist you see depends on the centre nearest you and on what your treatment involves. Tell us where you are and we will point you to the closest.

Talk it through

Reading about a medicine is not the same as being told what to expect

This page explains what the medicine does in general. What it cannot tell you is how your own regimen was chosen, what your schedule looks like, or which of these effects apply to you — that needs your reports and a conversation.

Free first consultation Second opinion on an existing plan 10 centres across Hyderabad

Speak to an oncologist

Share your details and the team will call you back to arrange a consultation or a second opinion.

Bring your reports if you have them. If you do not, come anyway.

list of links to other editorial pages, which base contract s2.1 permits explicitly. It contains no form, no phone number and no CTA button, so it does not turn this page into an advertisement. Generated by scripts/hub_update.py --include-out. -->

Full index